Asset profile

Pyrotinib

Small molecule

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. No upcoming registrational readout date is posted to the registry — check News for topline announcements.

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (8)

August 2026 (1)

Phase 1/2Breast Cancer Metastatic, Breast Cancer Brain MetastasesRecruiting

Est. primary completion 2026-08-31 · NCT06718933 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (1)

Phase 2Breast Cancer, Adjuvant TherapyRecruiting

Est. primary completion 2026-10-01 · NCT05292742 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (1)

Phase 2Breast CancerRecruiting

Est. primary completion 2026-11-01 · NCT06254690 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (5)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast CancerActive not recruiting

Est. primary completion 2026-12-01 · NCT04486911 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Breast CancerActive not recruiting

Est. primary completion 2026-12-01 · NCT04290793 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-12-31 · NCT05751018 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HER2-positive Breast CancerRecruiting

Est. primary completion 2026-12-31 · NCT07635342 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (11)

February 2027 (1)

Phase 1/2Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast CancerRecruiting

Est. primary completion 2027-02 · NCT07708194 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (1)

Phase 2HER2-positive Breast CancerNot yet recruiting

Est. primary completion 2027-05-31 · NCT06973525 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (2)

Phase 3Breast CancerActive not recruiting

Est. primary completion 2027-06 · NCT03980054 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast CancerNot yet recruiting

Est. primary completion 2027-06-01 · NCT06975475 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (2)

Phase 3Breast CancerNot yet recruiting

Est. primary completion 2027-08-01 · NCT04973319 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast NeoplasmsRecruiting

Est. primary completion 2027-08-15 · NCT04983121 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)

Phase 2HER2 + Breast CancerRecruiting

Est. primary completion 2027-09-30 · NCT07393425 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)

Phase 2Lung Cancer Stage III, MutationRecruiting

Est. primary completion 2027-11-01 · NCT06563999 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (3)

Phase 3Breast CancerRecruiting

Est. primary completion 2027-12 · NCT07528716 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting

Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast CancerRecruiting

Est. primary completion 2027-12-31 · NCT07014410 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (11)

January 2028 (1)

Phase 2HER2-positive Breast Cancer, Neoadjuvant Therapy, PyrotinibRecruiting

Est. primary completion 2028-01 · NCT06832904 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)

Phase 3Breast CancerNot yet recruiting

Est. primary completion 2028-05-06 · NCT05841381 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (1)

Phase 2HER2-positive Breast Cancer, Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-07-31 · NCT07019337 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)

Phase 2Metastatic Breast Cancer With HER2 PositiveNot yet recruiting

Est. primary completion 2028-08-30 · NCT07132242 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)

Phase 2Advanced Breast CancerRecruiting

Est. primary completion 2028-09 · NCT07180082 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)

Phase 2Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast CancerRecruiting

Est. primary completion 2028-11-01 · NCT07610720 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (5)

Phase 3Breast CancerRecruiting

Est. primary completion 2028-12-14 · NCT04646759 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-30 · NCT05769010 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Breast CancerRecruiting

Est. primary completion 2028-12-30 · NCT07615751 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Advanced/ Metastatic Her-2 Positive Breast CancerRecruiting

Est. primary completion 2028-12-31 · NCT05575804 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HER2-positive Early Breast CancerRecruiting

Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)

January 2029 (1)

Phase 2Breast Cancer, HER2-positive Breast CancerNot yet recruiting

Est. primary completion 2029-01-31 · NCT07417241 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (2)

April 2030 (1)

Phase 3Breast Cancer InvasiveRecruiting

Est. primary completion 2030-04 · NCT05910398 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)

Phase 2HER2-positive Breast CancerNot yet recruiting

Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (2)

June 2031 (1)

Phase 3HER2-positive Metastatic Breast Cancer, First-line TreatmentRecruiting

Est. primary completion 2031-06-30 · NCT06278870 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2031 (1)

Phase 2HER2 + Breast Cancer, Advanced Breast CancerNot yet recruiting

Est. primary completion 2031-12-31 · NCT07766772 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.